Retlirafusp Biosimilar – Anti-CD274 mAb – Research Grade from ProteoGenix; catalogue PX-TA1880; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Retlirafusp Biosimilar, also known as Anti-CD274 mAb, is a research grade antibody that has shown promising results in the field of cancer therapy. This biosimilar is a monoclonal antibody that specifically targets the CD274 protein, also known as programmed cell death ligand 1 (PD-L1). In this article, we will delve into the structure, activity, and potential applications of Retlirafusp Biosimilar.
Retlirafusp Biosimilar is a recombinant humanized monoclonal antibody that is produced using advanced genetic engineering techniques. It is composed of two identical heavy chains and two identical light chains, each consisting of approximately 450 amino acids. The antibody has a molecular weight of approximately 150 kDa.
The variable region of Retlirafusp Biosimilar is responsible for its specificity towards CD274 protein. This region is located at the tip of the antibody and is composed of six complementarity-determining regions (CDRs). These CDRs interact with specific amino acid sequences on the CD274 protein, allowing the antibody to bind to it with high affinity.
Retlirafusp Biosimilar exerts its activity by binding to the CD274 protein on the surface of cancer cells. CD274 protein is known to be overexpressed in various types of cancer, including lung, breast, and bladder cancer. This overexpression of CD274 protein allows cancer cells to evade the immune system and continue to grow and spread.
By binding to CD274 protein, Retlirafusp Biosimilar blocks its interaction with the programmed cell death protein 1 (PD-1) on immune cells. This interaction between CD274 and PD-1 is known to inhibit the activity of immune cells, allowing cancer cells to escape detection and destruction. By blocking this interaction, Retlirafusp Biosimilar enhances the activity of immune cells and promotes the destruction of cancer cells.
Retlirafusp Biosimilar has shown promising results in preclinical studies and is currently being evaluated in clinical trials for the treatment of various types of cancer. Some potential applications of this biosimilar include:
1. Treatment of Non-Small Cell Lung
Retlirafusp Biosimilar has shown significant anti-tumor activity in preclinical models of NSCLC. It has also shown to enhance the activity of other anti- cancer therapies, such as chemotherapy and radiotherapy. Clinical trials are currently ongoing to evaluate the efficacy and safety of Retlirafusp Biosimilar in NSCLC patients.
2. Treatment of Breast
In preclinical studies, Retlirafusp Biosimilar has shown to effectively inhibit the growth and spread of breast cancer cells. It has also shown to enhance the activity of other anti- cancer therapies, such as hormone therapy and targeted therapy. Clinical trials are currently underway to evaluate the potential of Retlirafusp Biosimilar in breast cancer treatment.
3. Treatment of Bladder
Retlirafusp Biosimilar has shown to be effective in preclinical models of bladder cancer by inhibiting the growth and spread of cancer cells. It has also shown to enhance the activity of other anti- cancer therapies, such as chemotherapy and immunotherapy. Clinical trials are currently ongoing to evaluate the potential of Retlirafusp Biosimilar in bladder cancer treatment.
4. Combination Therapy Retlirafusp Biosimilar has shown to enhance the activity of other anti- cancer therapies, making it a promising candidate for combination therapy. Clinical trials are currently underway to evaluate the potential of combining Retlirafusp Biosimilar with other anti- cancer agents for the treatment of various types of cancer.
In conclusion, Retlirafusp Biosimilar is a research grade antibody that specifically targets
ProteoGenix catalogue number PX-TA1880. For research use only.
Target: Retlirafusp Biosimilar – Anti-CD274 mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Retlirafusp Biosimilar – Anti-CD274 mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
